• <strike id="xmwty"><table id="xmwty"></table></strike>
    <progress id="xmwty"></progress>

      <b id="xmwty"></b>

      ×

      Tonghua Dongbao: First Patient Dosed in Phase Ib Clinical Trial of Dual GLP-1/GIP Receptor Agonist (THDBH120 Injection) for Diabetes Indications

      Date:2024-06-21
      Author:東寶
      Views:3

      Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company"), received the notice of approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the clinical trial of THDBH120 injection. The Phase Ib clinical trial for diabetes has been initiated, and the first patient was dosed recently.

       

      The dosing of the first patient in the Phase Ib trial represents a milestone in the clinical development of THDBH120, providing a solid foundation for subsequent research. Concurrently, the Phase Ia clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of THDBH120 injection in healthy Chinese adults is well underway, with the final cohort set to commence soon. The Company will accelerate the development of THDBH120 injection for both diabetes and weight loss indications, while exploring other potential uses to maximize the product's value.

       

      The future market of THDBH120 injection is promising. A comparable product, Tirzepatide, the world's first dual GLP-1/GIP receptor agonist, has seen rapid sales growth since its launch. Tirzepatide for diabetes (trade name: Mounjaro) was approved by the FDA and EMA in 2022, and its weight loss version (trade name: Zepbound) received FDA approval in November 2023. According to financial reports from Lilly, the global sales of Tirzepatide amounted to USD 5.34 billion in 2023 (2022: USD 0.48 billion) and USD 2.32 billion in 2024Q1.

       

      About THDBH120 injection (a dual GLP-1/GIP receptor agonist)

      THDBH120 injection is a dual-target agonist that acts on both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This drug integrates the effects of two incretins, GLP-1 and GIP, into a polypeptide monomer and improves metabolic stability through molecular design, synergistically promoting blood glucose control, weight loss, regulation of lipid metabolism, etc. It meets the clinical needs of diabetic patients who report poor effects of treatment with single molecular targets or compounded preparations. THDBH120 injection is expected to become a more long-acting blockbuster drug for treatment of diabetes and obesity. In addition to diabetes, the Company received clinical trial approval for THDBH120 injection for weight loss indications in April 2024.


      0 国产在线看片av免费,91中文字幕 国产,国产丝袜脚足j在线视频播放,黄视频在线观看无码免费
    1. <strike id="xmwty"><table id="xmwty"></table></strike>
      <progress id="xmwty"></progress>

        <b id="xmwty"></b>

        欧美在线一区观看| 日韩欧美P片内射在线海角| 欧美一区二| 四虎在线无码免费精品| 亚洲аv电影在线观看| 国产欧美日韩第一章午夜在线| 一级中文字幕免费乱码专区| 97精品伊人久久久大香线蕉97如何观看| 国产一级级在线观看m| 无码中文字幕av免| 亚洲欧美国产制服日本一区二区| 久久午夜福利免费无码| 亚洲视频在线观看一级片| 无码中文字幕加勒比精品| 国产无遮挡无套在线观看| 中文字幕精品亚洲人成在线| 久久久久国产一级毛片高清| 国产天天看在线观看| 精品久久久久久亚洲综合网| 亚洲人妻性感视频第二页| 无码专区之精品视频免费的| 动漫国产精品一区二区三区啊啊| 激情五月婷婷| 欧美精品一区二区蜜桃| 国产成精品在线观看| 亚洲成片在线观看中文无码| AV 无码 高潮 AV| 久久久久国产一区二区三区| 亚洲一级黄色网站电影|